Table 7.
Comparison of SNPs with the time spent in the therapeutic range.
| SNPs | Cyclosporine | Everolimus/Sirolimus | Tacrolimus | ||||
|---|---|---|---|---|---|---|---|
| Median (Range) Time Spent in Therapeutic Range (%) | p-Values a | Median (Range) Time Spent in Therapeutic Range (%) | p-Values a | Median (Range) Time Spent in Therapeutic Range (%) | p-Values a | ||
| CYP3A4*22 | GG | 50.2 (9–81) | 0.2 | 97 (52–100) | 0.3 | 90.5 (24.4–100) | 0.8 |
| GA | 63.8 (55–70) | 99 (44–100) | 75.8 (32.6–100) | ||||
| AA | 49.4 | NA | 87.1 (24.1–100) | ||||
| CYP3A5*3 | TT | 49.5 | 0.8 | 92.6 (85.2–100) | 0.7 | 91.8 (37.6–96.6) | 0.7 |
| CT | 54.7 (17–85) | 99.6 (96.1–100) | 90.1 (37.6–100) | ||||
| CC | 51 (9–81) | 96.3 (44–100) | 85.8 (24.1–100) | ||||
| ABCB1 | AA | 46.4 (35–52) | 0.04 * | 100 (99.2–100) | 0.05 * | 87.3 (38.7–99.1) | 0.2 |
| AG | 56.5 (17–81) | 96.6 (44–100) | 93.6 (31.1–100) | ||||
| GG | 40.5 (9–66) | 75.4 (60–100) | 85.6 (24.1–100) | ||||
| PPAR-alpha | AA | 55 (51–59) | 0.3 | 97 | 0.4 | 91.7 (89.6–96.5) | 0.8 |
| AG | 55.3 (35–70) | 100 (60–100) | 91.3 (24.1–100) | ||||
| GG | 49.2 (9–81) | 95.8 (44–100) | 87 (24.4–100) | ||||
| POR*28 | CC | 50.2 (9–81) | 0.6 | 93.9 (44–100) | 0.08 | 91.7 (24.4–100) | 0.4 |
| CT | 56.5 (17–70) | 100 (93–100) | 85.8 (24.1–100) | ||||
| TT | 47.6 (46–50) | 95.8 (69.9–97) | 87.6 (28.9–99.1) | ||||
| POR*28 activity | Normal | 51.4 (9–81) | 0.5 | 99.6 (44–100) | 0.07 | 90.5 (24.1–100) | 0.6 |
| Higher | 47.6 (46–50) | 95.8 (69.9–97) | 87.6 (28.9–99.1) | ||||
a-for differences between the genotypes *-Statistically significant (p ≤ 0.05).